There are two phase 3 trials busy right now: 1st trial is a 24 week combination therapy (140 in combo with HAART) which is done with 30 patients which started October 2015. The endpoint is Q1 2017 and the BLA will also be submitted in 2017. The 2nd trial is a 48 week mono therapy which has 300 patients and started enrollment December 2016.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.